Publication Name	World Journal of Transplantation
Manuscript ID	9678
Country	Spain

Received	2014-02-24 09:04
Peer-Review Started	2014-02-24 21:18
To Make the First Decision	2014-03-26 15:14
Return for Revision	2014-03-31 15:33
Revised	2014-04-14 21:06
Second Decision	2014-05-29 15:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-05-29 16:01
Articles in Press	2014-05-29 16:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-06-30 10:26
Publish the Manuscript Online	2014-07-20 20:07

ISSN	2220-3230 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Autobiography
Article Title	Multiple indications for everolimus after liver transplantation in current clinical practice
Manuscript Source	Invited Manuscript
All Author List	Itxarone Bilbao, Cristina Dopazo, Jose Lazaro, Lluis Castells, Mireia Caralt, Gonzalo Sapisochin and Ramon Charco
Funding Agency and Grant Number
Corresponding Author	Itxarone Bilbao, MD, PhD, Hepatobiliopancreatic Surgery and Liver Transplant Unit of the Department of General Surgery, Hospital Vall Hebrón, Universidad Autónoma Barcelona, Paseo Vall d′Hebron, 119-129, 08035 Barcelona, Spain. ibilbao@vhebron.net
Key Words	Everolimus; Liver transplantation; Indications; Off-protocol; Outcome
Core Tip	Everolimus has a completely different mechanism of action to that of current basal calcineurine inhibitors used worldwide in liver transplantation. This immunosuppressant has a good profile for patients with pre- and post transplant renal dysfunction, one of the main concerns nowadays. It has also a promising role in cancer patients which is common in liver transplantation, either as an underlying disease (hepatocarcinoma in cirrhosis), or as de novo developing tumors. We present our off-protocol experience with partial/total and early/late conversion to everolimus, highlighting its efficacy and safety in fitting with the different emerging scenarios after liver transplantation.
Publish Date	2014-07-20 20:07
Citation	Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G, Charco R. Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant 2014; 4(2): 122-132
URL	http://www.wjgnet.com/2220-3230/full/v4/i2/122.htm
DOI	http://dx.doi.org/10.5500/wjt.v4.i2.122

Full Article (PDF)	WJT-4-122.pdf
Full Article (Word)	WJT-4-122.doc
Manuscript File	9678-Review.doc
Answering Reviewers	9678-Answering reviewers.pdf
Copyright License Agreement	9678-Copyright assignment.pdf
Peer-review Report	9678-Peer review(s).pdf
Scientific Misconduct Check	9678-CrossCheck.jpg
Scientific Editor Work List	9678-Scientific editor work list.pdf